• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变型p53在慢性相对缺氧反应中促进促血管生成、过度增殖表型。

Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia.

作者信息

Kamat Chandrashekhar D, Green Dixy E, Warnke Linda, Thorpe Jessica E, Ceriello Antonio, Ihnat Michael A

机构信息

Department of Cell Biology, University of Oklahoma Health Sciences Center, 726 BMSB, 940 S.L. Young Boulevard, Oklahoma City, OK, USA.

出版信息

Cancer Lett. 2007 May 8;249(2):209-19. doi: 10.1016/j.canlet.2006.08.017. Epub 2006 Sep 25.

DOI:10.1016/j.canlet.2006.08.017
PMID:16997458
Abstract

There is much controversy in the literature regarding the role of p53 status response on hypoxia inducible factor (HIF) signaling in response to chronic relative hypoxia (CRH). The goal of this paper was to methodically examine this response in isogenically matched tumor cells. We report that p53-mutant (MUT) cells, versus p53-wild-type (WT) cells, showed decreased apoptosis, increased cell proliferation with higher basal HIF-1alpha levels in response to CRH. In addition, we found increased HIF-mediated transactivation and increased VEGF release with decreased HIF-1alpha/p53 and HIF-1alpha/MDM-2 partnering in p53-MUT versus p53-WT cells in response to CRH.

摘要

关于p53状态反应在慢性相对缺氧(CRH)反应中对缺氧诱导因子(HIF)信号传导的作用,文献中存在很多争议。本文的目的是系统地研究同基因匹配的肿瘤细胞中的这种反应。我们报告,与p53野生型(WT)细胞相比,p53突变型(MUT)细胞在CRH反应中显示出凋亡减少、细胞增殖增加以及基础HIF-1α水平升高。此外,我们发现,在CRH反应中,与p53-WT细胞相比,p53-MUT细胞中HIF介导的反式激活增加、VEGF释放增加,而HIF-1α/p53和HIF-1α/MDM-2的结合减少。

相似文献

1
Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia.突变型p53在慢性相对缺氧反应中促进促血管生成、过度增殖表型。
Cancer Lett. 2007 May 8;249(2):209-19. doi: 10.1016/j.canlet.2006.08.017. Epub 2006 Sep 25.
2
Pro-angiogenic effects of MDM2 through HIF-1α and NF-κB mediated mechanisms in LNCaP prostate cancer cells.MDM2在LNCaP前列腺癌细胞中通过HIF-1α和NF-κB介导的机制产生促血管生成作用。
Mol Biol Rep. 2014 Aug;41(8):5533-41. doi: 10.1007/s11033-014-3430-0. Epub 2014 Jun 28.
3
CSB modulates the competition between HIF-1 and p53 upon hypoxia.CSB 调节低氧条件下 HIF-1 和 p53 之间的竞争。
Math Biosci Eng. 2019 Jun 10;16(5):5247-5262. doi: 10.3934/mbe.2019262.
4
Modeling the interplay between the HIF-1 and p53 pathways in hypoxia.模拟缺氧状态下HIF-1与p53信号通路之间的相互作用
Sci Rep. 2015 Sep 8;5:13834. doi: 10.1038/srep13834.
5
BP-1T, an antiangiogenic benzophenone-thiazole pharmacophore, counteracts HIF-1 signalling through p53/MDM2-mediated HIF-1α proteasomal degradation.BP-1T是一种具有抗血管生成作用的二苯甲酮-噻唑药效团,通过p53/MDM2介导的HIF-1α蛋白酶体降解来对抗HIF-1信号传导。
Angiogenesis. 2017 Feb;20(1):55-71. doi: 10.1007/s10456-016-9528-3. Epub 2016 Oct 14.
6
Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia.缺氧条件下肿瘤细胞中Mdm2与HIF-1α的相互作用
J Cell Physiol. 2005 Aug;204(2):364-9. doi: 10.1002/jcp.20406.
7
Expression of p53 protein in esophageal squamous cell carcinoma: relation to hypoxia-inducible factor-1alpha, angiogenesis and apoptosis.p53蛋白在食管鳞状细胞癌中的表达:与缺氧诱导因子-1α、血管生成及细胞凋亡的关系
Pathobiology. 2005;72(4):179-85. doi: 10.1159/000086787.
8
Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells.慢病毒介导的HIF-1α基因敲低对纤维肉瘤细胞中缺氧相关顺铂耐药性的影响及其对p53状态的依赖性
Cancer Gene Ther. 2008 Jul;15(7):449-55. doi: 10.1038/cgt.2008.4. Epub 2008 Apr 18.
9
Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia.去磷酸化的缺氧诱导因子1α作为缺氧期间p53依赖性细胞凋亡的介质。
Oncogene. 2001 Sep 13;20(41):5779-88. doi: 10.1038/sj.onc.1204742.
10
p53 inhibits vascular endothelial growth factor expression in solid tumor.p53 抑制实体瘤中血管内皮生长因子的表达。
J Surg Res. 2012 May 15;174(2):291-7. doi: 10.1016/j.jss.2010.12.028. Epub 2011 Jan 15.

引用本文的文献

1
TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization.TP53突变预示经动脉栓塞治疗的肝细胞癌患者生存期更差且局部进展更早。
Curr Oncol. 2025 Jan 18;32(1):51. doi: 10.3390/curroncol32010051.
2
Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.调节p53-MDM2信号通路:天然化合物在癌症治疗中的治疗潜力。
EXCLI J. 2024 Nov 22;23:1397-1439. doi: 10.17179/excli2024-7791. eCollection 2024.
3
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer.
尼达尼布在分子筛选的晚期非小细胞肺癌患者中的一项初步研究。
J Thorac Dis. 2024 Jun 30;16(6):3782-3793. doi: 10.21037/jtd-23-1717. Epub 2024 Jun 12.
4
New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.肝细胞癌局部区域治疗的机制与干预新见解。
Chin J Cancer Res. 2024 Apr 30;36(2):167-194. doi: 10.21147/j.issn.1000-9604.2024.02.06.
5
Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression.法尼基转移酶抑制剂通过抑制炎症和缺氧诱导因子-1α表达抑制 NASH 相关 HCC。
Int J Mol Sci. 2023 Jul 17;24(14):11546. doi: 10.3390/ijms241411546.
6
Therapeutic Potential of Nanomedicine in Management of Alzheimer's Disease and Glioma.纳米医学在阿尔茨海默病和神经胶质瘤治疗中的应用潜力
Int J Nanomedicine. 2023 May 22;18:2737-2756. doi: 10.2147/IJN.S405454. eCollection 2023.
7
A case report of the sustained and rapid response of bevacizumab in a TP53-positive breast cancer and liver metastatic patient through personalized medicine.一例通过精准医疗使用贝伐单抗治疗TP53阳性乳腺癌伴肝转移患者获得持续快速缓解的病例报告。
Front Oncol. 2022 Sep 2;12:940678. doi: 10.3389/fonc.2022.940678. eCollection 2022.
8
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.TP53 突变和 miR 对胰腺癌进展中肿瘤微环境免疫反应的影响。
Cells. 2022 Jul 9;11(14):2155. doi: 10.3390/cells11142155.
9
It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy.情况愈发复杂——重新审视肿瘤发生与癌症治疗中的p53-MDM2-ARF三角关系
Front Cell Dev Biol. 2022 Jan 26;10:818744. doi: 10.3389/fcell.2022.818744. eCollection 2022.
10
Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms.氧化还原敏感半胱氨酸残基作为野生型和突变型 p53 异构体的关键调节剂。
Cells. 2021 Nov 12;10(11):3149. doi: 10.3390/cells10113149.